UA117182C2 - Нові композиції, їх використання і способи одержання - Google Patents

Нові композиції, їх використання і способи одержання

Info

Publication number
UA117182C2
UA117182C2 UAA201612474A UAA201612474A UA117182C2 UA 117182 C2 UA117182 C2 UA 117182C2 UA A201612474 A UAA201612474 A UA A201612474A UA A201612474 A UAA201612474 A UA A201612474A UA 117182 C2 UA117182 C2 UA 117182C2
Authority
UA
Ukraine
Prior art keywords
methods
making
novel compositions
present
compounds
Prior art date
Application number
UAA201612474A
Other languages
English (en)
Inventor
Мустафа ХАДДАХ
Original Assignee
Паймера, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54393079&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117182(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Паймера, Інк. filed Critical Паймера, Інк.
Publication of UA117182C2 publication Critical patent/UA117182C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Загалом, даний винахід надає нові сполуки хінолонів і їх фармацевтичну композицію, які можуть інгібувати клітинну проліферацію і/або індукувати апоптоз клітин. Даний винахід також стосується способів одержання таких сполук і композицій, а також способів їх створення і використання.
UAA201612474A 2014-05-09 2015-05-09 Нові композиції, їх використання і способи одержання UA117182C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991282P 2014-05-09 2014-05-09
US201462050202P 2014-09-15 2014-09-15
US201462054054P 2014-09-23 2014-09-23
US201562128208P 2015-03-04 2015-03-04
PCT/US2015/030046 WO2015172123A1 (en) 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them

Publications (1)

Publication Number Publication Date
UA117182C2 true UA117182C2 (uk) 2018-06-25

Family

ID=54393079

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201612474A UA117182C2 (uk) 2014-05-09 2015-05-09 Нові композиції, їх використання і способи одержання

Country Status (32)

Country Link
US (1) US9512123B2 (uk)
EP (2) EP3219716A1 (uk)
JP (2) JP6188179B2 (uk)
KR (3) KR102044648B1 (uk)
CN (2) CN106459068B (uk)
AU (3) AU2015255738C1 (uk)
BR (1) BR112016026150B1 (uk)
CA (2) CA2974960A1 (uk)
CL (2) CL2016002798A1 (uk)
CY (1) CY1120935T1 (uk)
DK (1) DK3140305T3 (uk)
EA (1) EA034235B1 (uk)
EC (3) ECSP16088687A (uk)
ES (1) ES2679628T3 (uk)
HR (1) HRP20181105T1 (uk)
HU (1) HUE039733T2 (uk)
IL (2) IL248638B (uk)
LT (1) LT3140305T (uk)
MX (1) MX2016014555A (uk)
NI (1) NI201600168A (uk)
NZ (1) NZ725917A (uk)
PE (2) PE20170131A1 (uk)
PH (2) PH12016502213A1 (uk)
PL (1) PL3140305T3 (uk)
PT (1) PT3140305T (uk)
RS (1) RS57493B1 (uk)
SG (2) SG11201609171XA (uk)
SI (1) SI3140305T1 (uk)
TR (1) TR201809990T4 (uk)
UA (1) UA117182C2 (uk)
WO (1) WO2015172123A1 (uk)
ZA (1) ZA201607573B (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CN110709400A (zh) * 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112300173B (zh) * 2019-07-30 2021-10-01 上海凌达生物医药有限公司 一类含氮多环类化合物、制备方法和用途
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CN110606850A (zh) * 2019-09-11 2019-12-24 中山大学 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113416197B (zh) * 2021-08-25 2021-12-28 北京鑫开元医药科技有限公司 甲酰胺类衍生物、制备方法、药物组合物及应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) * 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) * 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
CA2138791A1 (en) * 1992-06-22 1994-01-06 Dietrich Arndts 9-aminopyridazino[4',5':3,4]pyrrolo[2,1-a]isoquinolines and their use in the preparation of pharmaceutical compositions
DE19509043A1 (de) * 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
AU1182702A (en) * 2000-10-03 2002-04-15 Bristol Myers Squibb Co Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US7141565B1 (en) 2003-04-07 2006-11-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
AU2005286965B2 (en) 2004-09-17 2009-10-22 Senhwa Biosciences, Inc. Quinolone analogs as cell proliferation inhibitors
ITMI20042476A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Derivati indolici ad attivita' antitumorale
WO2006113509A2 (en) 2005-04-15 2006-10-26 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and methods of using thereof
PT1928887E (pt) 2005-08-05 2015-02-12 Senhwa Biosciences Inc Métodos de preparação de análogos de quinolona
WO2007038215A1 (en) * 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20100063046A1 (en) * 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
DE102006051796A1 (de) 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
WO2008156879A1 (en) 2007-06-20 2008-12-24 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
PL3092901T3 (pl) 2007-10-05 2020-10-19 Senhwa Biosciences, Inc. Analogi chinolonu i sposoby z nimi związane
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
CN103333167B (zh) 2008-11-03 2016-08-24 株式会社Lg化学 新的含氮杂环化合物及使用该化合物的有机电子器件
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
CN103533934B (zh) * 2011-03-17 2016-03-30 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
KR101561730B1 (ko) * 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자

Also Published As

Publication number Publication date
SG11201609171XA (en) 2016-12-29
LT3140305T (lt) 2018-09-10
CA2948173C (en) 2018-06-19
PL3140305T3 (pl) 2018-10-31
IL264454A (en) 2019-02-28
JP2017101038A (ja) 2017-06-08
PT3140305T (pt) 2018-07-24
US9512123B2 (en) 2016-12-06
EP3140305A1 (en) 2017-03-15
SI3140305T1 (sl) 2018-09-28
PH12016502213B1 (en) 2017-01-16
IL248638B (en) 2019-02-28
RS57493B1 (sr) 2018-10-31
PE20170678A1 (es) 2017-06-03
ECSP16088687A (es) 2017-01-31
DK3140305T3 (en) 2018-07-30
KR20180118806A (ko) 2018-10-31
CN106995443A (zh) 2017-08-01
JP6188179B2 (ja) 2017-08-30
PE20170131A1 (es) 2017-03-19
EA201692269A1 (ru) 2017-04-28
MX2016014555A (es) 2017-05-30
KR20160144509A (ko) 2016-12-16
TR201809990T4 (en) 2018-08-27
PH12016502213A1 (en) 2017-01-16
SG10201703658SA (en) 2017-06-29
AU2015255738B2 (en) 2017-04-27
US20160326176A1 (en) 2016-11-10
EA034235B1 (ru) 2020-01-20
CA2948173A1 (en) 2015-11-12
BR112016026150B1 (pt) 2019-11-05
EP3140305B1 (en) 2018-04-18
CN106995443B (zh) 2022-01-11
CN106459068B (zh) 2019-01-22
CN106459068A (zh) 2017-02-22
HRP20181105T1 (hr) 2018-09-21
AU2017203955A1 (en) 2017-07-06
HUE039733T2 (hu) 2019-01-28
CL2016002798A1 (es) 2017-03-10
WO2015172123A1 (en) 2015-11-12
CA2974960A1 (en) 2015-11-12
AU2017202145A1 (en) 2017-04-20
ZA201607573B (en) 2018-08-30
PH12017500660A1 (en) 2019-03-04
AU2015255738C1 (en) 2017-09-28
KR102044648B1 (ko) 2019-11-13
KR101890505B1 (ko) 2018-09-28
CL2017000372A1 (es) 2017-09-08
KR20170042821A (ko) 2017-04-19
EP3140305A4 (en) 2017-03-15
CY1120935T1 (el) 2019-12-11
NZ725917A (en) 2017-07-28
ECSP18049420A (es) 2018-07-31
EP3219716A1 (en) 2017-09-20
ECSP17031525A (es) 2017-06-30
ES2679628T3 (es) 2018-08-29
AU2015255738A1 (en) 2016-11-24
NI201600168A (es) 2017-01-26
AU2017202145B2 (en) 2019-02-21
JP2017514889A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
PH12017500660A1 (en) Novel compositions, uses and methods for making them
PH12018500907A1 (en) Inhibitors of ret
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018011194A (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
WO2015120062A3 (en) Therapeutic compounds and compositions
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
IN2014CH00840A (uk)
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
NZ721832A (en) Solid forms of tenofovir
IN2014MU00197A (uk)
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016015468A (es) Composiciones farmaceuticas que contienen montelukast y levocetirizina.
IN2014MU00815A (uk)
IN2014MU00814A (uk)